Atara Biotherapeutics, Inc.
NASDAQ:ATRA
11.4 (USD) • At close December 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 8.573 | 63.573 | 20.34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 8.886 | 14.568 | 11.38 | 9.867 | 8.105 | 3.781 | 0.956 | 0.383 | 0.048 | 0 | 0 | 0 |
| Gross Profit
| -0.313 | 49.005 | 8.96 | -9.867 | -8.105 | -3.781 | -0.956 | -0.383 | -0.048 | 0 | 0 | 0 |
| Gross Profit Ratio
| -0.037 | 0.771 | 0.441 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 224.785 | 272.533 | 282.001 | 244.65 | 216.097 | 167.457 | 81.206 | 56.514 | 41.618 | 15.446 | 4.859 | 9.777 |
| General & Administrative Expenses
| 50.908 | 71.553 | 78.801 | 64.402 | 79.584 | 69.654 | 40.326 | 24.728 | 16.83 | 12.71 | 3.756 | 2.502 |
| Selling & Marketing Expenses
| -1.111 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 49.797 | 71.553 | 78.801 | 64.402 | 79.584 | 69.654 | 40.326 | 24.728 | 16.83 | 12.71 | 3.756 | 2.502 |
| Other Expenses
| 0 | -0.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.066 | 0 | 0 |
| Operating Expenses
| 275.693 | 344.086 | 360.802 | 309.052 | 295.681 | 237.111 | 121.532 | 81.242 | 58.448 | 28.156 | 8.615 | 12.279 |
| Operating Income
| -276.006 | -280.513 | -340.462 | -309.052 | -295.681 | -237.111 | -121.532 | -81.242 | -58.448 | -28.156 | -8.615 | -3.225 |
| Operating Income Ratio
| -32.195 | -4.412 | -16.739 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -0.105 | 52.223 | 0.367 | 2.447 | 4.717 | 6.368 | 2.027 | 2.203 | 1.218 | 0.125 | 0.012 | -0.868 |
| Income Before Tax
| -276.111 | -228.29 | -340.095 | -306.605 | -290.964 | -230.743 | -119.505 | -79.039 | -57.23 | -28.031 | -8.603 | -12.279 |
| Income Before Tax Ratio
| -32.207 | -3.591 | -16.721 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.015 | 0.012 | 0.046 | 0.015 | 0.012 | -0.044 | -0.014 | 0.01 | -0.009 | -0.025 | 0.17 | 0.051 |
| Net Income
| -276.126 | -2,283.02 | -3,401.41 | -3,066.2 | -2,909.76 | -2,306.99 | -1,194.91 | -790.49 | -572.21 | -280.06 | -87.73 | -123.3 |
| Net Income Ratio
| -32.209 | -35.912 | -167.228 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -65.18 | -55.96 | -90.78 | -103.63 | -141.78 | -131.64 | -100.03 | -68.78 | -55.92 | -140.42 | -227.09 | -16.81 |
| EPS Diluted
| -65.18 | -55.96 | -90.78 | -103.63 | -141.78 | -131.64 | -100.03 | -68.78 | -55.92 | -140.42 | -227.09 | -16.81 |
| EBITDA
| -265.997 | -213.722 | -331.117 | -296.738 | -282.859 | -233.33 | -120.576 | -80.859 | -58.4 | -28.15 | -8.611 | -4.093 |
| EBITDA Ratio
| -31.027 | -5.203 | -16.739 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |